At some level this summer season, the drugmaker Novo Nordisk will launch outcomes from a intently watched examine that, if profitable, might additional uncork demand for brand spanking new weight problems drugs, streamline insurance coverage protection for the therapies, and exhibit long-lasting well being advantages.
The Choose trial, because the examine known as, is the primary giant, randomized trial to check whether or not long-term remedy with a weight reduction drug can meaningfully enhance sufferers’ cardiovascular well being. Novo is testing Wegovy, a weekly injection additionally offered underneath the model identify Ozempic for sort 2 diabetes, in opposition to placebo within the five-year examine.
The implications are large, and never only for Novo. Wegovy is a part of a category of medicines that concentrate on a hormone known as GLP-1, which curbs sufferers’ appetites. These medicine have demonstrated a capability to assist individuals lose dramatic quantities of weight in medical trials, however payers, together with Medicare, have been sluggish to reimburse for them with out definitive knowledge on their long-term well being advantages.
Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!
GET STARTED